December 8, 2021 Non Regulatory InDex Pharmaceuticals enrols first patient in the PK study with cobitolimod Read more
December 8, 2021 Non Regulatory InDex Pharmaceuticals inkluderar första patienten i PK-studien med cobitolimod Read more
November 24, 2021 Regulatory InDex Pharmaceuticals enrols first patient in the phase III study CONCLUDE with cobitolimod in ulcerative colitis Read more
November 24, 2021 Regulatory InDex Pharmaceuticals inkluderar första patienten i fas III-studien CONCLUDE med cobitolimod i ulcerös kolit Read more
November 24, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – september 2021 Read more
November 24, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2021 Read more
November 16, 2021 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in Canada Read more
November 16, 2021 Regulatory InDex Pharmaceuticals får nytt patent för cobitolimod beviljat i Kanada Read more
November 10, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2022 Annual General Meeting Read more
November 10, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2022 Read more
November 9, 2021 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in the US Read more
November 9, 2021 Regulatory InDex Pharmaceuticals får nytt patent för cobitolimod beviljat i USA Read more
November 8, 2021 Non Regulatory InDex Pharmaceuticals presents at Redeye Life Science Day 2021 Read more
November 8, 2021 Non Regulatory InDex Pharmaceuticals presenterar på Redeye Life Science Day 2021 Read more
August 25, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2021 Read more
August 25, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2021 Read more
August 24, 2021 Regulatory InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod Read more
August 24, 2021 Regulatory InDex Pharmaceuticals får FDA-godkännande att starta fas III-studien CONCLUDE med cobitolimod Read more
August 23, 2021 Non Regulatory InDex Pharmaceuticals strengthens the clinical development organization in preparation of the start of the phase III study CONCLUDE with cobitolimod Read more
August 23, 2021 Non Regulatory InDex Pharmaceuticals stärker sin kliniska utvecklingsorganisation inför starten av fas III-studien CONCLUDE med cobitolimod Read more
July 21, 2021 Regulatory InDex Pharmaceuticals receives first regulatory approval to start the phase III study CONCLUDE with cobitolimod Read more
July 21, 2021 Regulatory InDex Pharmaceuticals får första regulatoriska godkännandet att starta fas III-studien CONCLUDE med cobitolimod Read more
June 3, 2021 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 31, 2021 Regulatory InDex Pharmaceuticals inleder patientrekryteringen till fas III-studien CONCLUDE efter sommaren Read more
May 31, 2021 Regulatory InDex Pharmaceuticals will initiate patient recruitment for the Phase III study CONCLUDE after the summer Read more
May 5, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2021 Read more
May 5, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – mars 2021 Read more
May 4, 2021 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 23, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2020 Read more
April 23, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2020 Read more
April 7, 2021 Non Regulatory InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe Read more
April 7, 2021 Non Regulatory InDex Pharmaceuticals får patent på ytterligare DIMS-substanser beviljat i Europa Read more
March 30, 2021 Non Regulatory InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis Read more
March 30, 2021 Non Regulatory InDex Pharmaceuticals ingår avtal med Parexel Biotech för klinisk fas III-studie med cobitolimod Read more
March 15, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting Read more
March 15, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) meddelar förändringar i valberedningens sammansättning inför årsstämman 2021 Read more
March 10, 2021 Non Regulatory InDex Pharmaceuticals presents at Barclays Global Healthcare Conference and Carnegie Nordic Virtual Healthcare Seminar Read more
March 10, 2021 Non Regulatory InDex Pharmaceuticals presenterar på Barclays Global Healthcare Conference och Carnegie Nordic Virtual Healthcare Seminar Read more
February 25, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2020 Read more
January 21, 2021 Regulatory InDex Pharmaceuticals Holding AB publishes prospectus in connection with a fully guaranteed rights issue Read more
January 21, 2021 Regulatory InDex Pharmaceuticals Holding AB offentliggör prospekt i samband med fullt garanterad företrädesemission Read more
January 14, 2021 Regulatory The board of directors of InDex Pharmaceuticals Holding AB has resolved on a fully guaranteed rights issue of approximately MSEK 533 Read more
January 14, 2021 Regulatory Styrelsen för InDex Pharmaceuticals Holding AB har beslutat om en fullt garanterad företrädesemission om cirka 533 miljoner kronor Read more
January 12, 2021 Regulatory Bulletin from the Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
January 12, 2021 Regulatory Kommuniké från extra bolagsstämma i InDex Pharmaceuticals Holding AB (publ) Read more